Rabbit Polyclonal ADAMTS19 Antibody

+ +

•  

   

     The image is immunohistochemistry of paraffin-embedded Human brain tissue using P04254(ADAMTS19 Antibody) at dilution 1/25. (Original magnification: ×200)    

  
  

The ADAMTS19 antibody is designed to target the ADAMTS19 protein, a member of the ADAMTS (A Disintegrin and Metalloproteinase with Thrombospondin Motifs) family. This family comprises secreted zinc-dependent proteases involved in extracellular matrix (ECM) remodeling, cell adhesion, and proteolytic processing of bioactive molecules. ADAMTS19. encoded by the ADAMTS19 gene on human chromosome 5. shares structural features with other family members, including a propeptide, catalytic domain, disintegrin-like module, thrombospondin type 1 (TSP1) repeats, and a C-terminal ancillary domain. Its precise biological functions remain less characterized compared to other ADAMTS proteases (e.g., ADAMTS13 in von Willebrand factor cleavage). However, emerging studies suggest roles in connective tissue homeostasis, skeletal development, and reproductive system regulation. Dysregulation of ADAMTS19 has been tentatively linked to pathologies such as osteoarthritis, cardiovascular diseases, and cancer progression, though mechanistic insights are limited.

ADAMTS19 antibodies are primarily used as research tools to detect protein expression, localization, and activity in tissues or cell lines. Polyclonal or monoclonal antibodies are generated against specific epitopes (e.g., catalytic or TSP1 domains) and validated via techniques like Western blotting, immunohistochemistry (IHC), or immunofluorescence (IF). Their applications include studying ADAMTS19's involvement in ECM dynamics, signaling pathways, and disease models. Commercial availability varies, with some antibodies optimized for human, mouse, or rat homologs. Challenges include ensuring specificity due to structural similarities among ADAMTS family members. Recent interest in ADAMTS19 as a potential therapeutic target or biomarker underscores the need for well-validated antibodies to advance functional and clinical research.